BIIB Covered Call Strategy
BIIB (Biogen Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NASDAQ.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc.
BIIB (Biogen Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $30.20B, a trailing P/E of 21.94, a beta of 0.20 versus the broader market, a 52-week range of 119.18-205.97, average daily share volume of 1.1M, a public-listing history dating back to 1991, approximately 8K full-time employees. These structural characteristics shape how BIIB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.20 indicates BIIB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a covered call on BIIB?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current BIIB snapshot
As of May 15, 2026, spot at $193.94, ATM IV 31.56%, IV rank 15.29%, expected move 9.05%. The covered call on BIIB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this covered call structure on BIIB specifically: BIIB IV at 31.56% is on the cheap side of its 1-year range, which means a premium-selling BIIB covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 9.05% (roughly $17.55 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BIIB expiries trade a higher absolute premium for lower per-day decay. Position sizing on BIIB should anchor to the underlying notional of $193.94 per share and to the trader's directional view on BIIB stock.
BIIB covered call setup
The BIIB covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BIIB near $193.94, the first option leg uses a $205.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BIIB chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BIIB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $193.94 | long |
| Sell 1 | Call | $205.00 | $2.25 |
BIIB covered call risk and reward
- Net Premium / Debit
- -$19,169.00
- Max Profit (per contract)
- $1,331.00
- Max Loss (per contract)
- -$19,168.00
- Breakeven(s)
- $191.69
- Risk / Reward Ratio
- 0.069
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
BIIB covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on BIIB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$19,168.00 |
| $42.89 | -77.9% | -$14,879.99 |
| $85.77 | -55.8% | -$10,591.98 |
| $128.65 | -33.7% | -$6,303.97 |
| $171.53 | -11.6% | -$2,015.96 |
| $214.41 | +10.6% | +$1,331.00 |
| $257.29 | +32.7% | +$1,331.00 |
| $300.17 | +54.8% | +$1,331.00 |
| $343.05 | +76.9% | +$1,331.00 |
| $385.93 | +99.0% | +$1,331.00 |
When traders use covered call on BIIB
Covered calls on BIIB are an income strategy run on existing BIIB stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
BIIB thesis for this covered call
The market-implied 1-standard-deviation range for BIIB extends from approximately $176.39 on the downside to $211.49 on the upside. A BIIB covered call collects premium on an existing long BIIB position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether BIIB will breach that level within the expiration window. Current BIIB IV rank near 15.29% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BIIB at 31.56%. As a Healthcare name, BIIB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BIIB-specific events.
BIIB covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BIIB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BIIB alongside the broader basket even when BIIB-specific fundamentals are unchanged. Short-premium structures like a covered call on BIIB carry tail risk when realized volatility exceeds the implied move; review historical BIIB earnings reactions and macro stress periods before sizing. Always rebuild the position from current BIIB chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on BIIB?
- A covered call on BIIB is the covered call strategy applied to BIIB (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With BIIB stock trading near $193.94, the strikes shown on this page are snapped to the nearest listed BIIB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BIIB covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the BIIB covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 31.56%), the computed maximum profit is $1,331.00 per contract and the computed maximum loss is -$19,168.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BIIB covered call?
- The breakeven for the BIIB covered call priced on this page is roughly $191.69 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BIIB market-implied 1-standard-deviation expected move is approximately 9.05%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on BIIB?
- Covered calls on BIIB are an income strategy run on existing BIIB stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current BIIB implied volatility affect this covered call?
- BIIB ATM IV is at 31.56% with IV rank near 15.29%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.